Background: Osteoporosis is a well-known complication of Crohn's disease (CD). Osteoprotegerin (OPG) concentration is elevated in patients with CD compared to healthy controls. Long-term infliximab (IFX) maintenance therapy improves the patients' bone mineral density. The effect of IFX on bone metabolism has not yet been clarified. Our aim was to evaluate IFX effects on bone pathology in CD patients.

Methods: Twenty-nine patients were treated with IFX as an induction therapy according to international guidelines at weeks 0, 2, and 6. Serum concentrations of biochemical markers of bone formation (osteocalcin, OC) and bone resorption (beta-crosslaps, bCL), and serum concentrations of OPG and receptor activator of nuclear factor kappa B ligand (sRANKL) were measured before every treatment at days 1, 14, and 42.

Results: Serum levels of OC and sRANKL increased after treatment. OC concentrations were 28.93 +/- 14.95 ng/mL versus 36.33 +/- 20.05 ng/mL (P < 0.005) at days 1 and 42, respectively; sRANKL concentrations were elevated from 0.0112 +/- 0.028 ng/mL to 0.0411 +/- 0.123 ng/mL (NS) by the end of the study. The concentrations of both bCL and OPG decreased. bCL concentrations were 0.636 +/- 0.594 versus 0.519 +/- 0.235 (NS) at days 1 and 42, respectively, while OPG concentration decreased from 3.739 +/- 1.485 to 3.491 +/- 1.618 (P < 0,05).

Conclusions: IFX therapy decreased the OPG concentration in CD patients significantly. In parallel, the serum bone resorption marker (bCL) also decreased. Concentrations of bone formation marker (OC) and sRANKL increased during the same period; however, those changes were not statistically significant. Elevated OPG in CD could be a counter-regulatory response to inflammatory cytokines or may reflect T-cell activation.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ibd.20234DOI Listing

Publication Analysis

Top Keywords

opg concentration
12
concentrations
8
crohn's disease
8
serum concentrations
8
bone formation
8
bone resorption
8
srankl increased
8
+/-
8
bone
7
opg
6

Similar Publications

Sclerostin and OPG/RANK-L system take part in bone remodeling in patients with acromegaly.

Front Endocrinol (Lausanne)

January 2025

Department and Clinic of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, Wrocław, Poland.

Article Synopsis
  • Acromegaly is marked by increased bone turnover and higher vertebral fracture risk, with sclerostin inhibiting bone formation and playing a role in the OPG/RANK-L system that regulates bone metabolism.
  • The study investigated levels of sclerostin, osteoprotegerin (OPG), and RANK-L in 126 patients with varying acromegaly activity, aiming to explore connections between sclerostin and bone health.
  • Results showed lower sclerostin levels in acromegaly patients compared to controls, with notable differences in OPG levels across groups but no significant changes in RANK-L; a positive correlation was found between sclerostin and OPG in patients with various acromegaly
View Article and Find Full Text PDF

Rehmanniae Radix Preparata, a processed form of the traditional Chinese medicinal plant Rehmannia glutinosa Libosch, has long been valued for its medicinal properties and use as a food. It is notably effective in treating postmenopausal osteoporosis. This study utilized C18 to separate and purify different concentrations of its eluent streams.

View Article and Find Full Text PDF

Perfluorooctane sulfonate (PFOS) induced bone loss by inhibiting FoxO1-mediated defense against oxidative stress in osteoblast.

Ecotoxicol Environ Saf

December 2024

Division of Chemical Toxicity and Safety Assessment, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China; State Environmental Protection Key Laboratory of Environmental Health Impact Assessment of Emerging Contaminants, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China. Electronic address:

Exposure to perfluorooctane sulfonate (PFOS) has been associated with lower bone density and the occurrence of osteoporosis in human studies, but the effects and mechanisms of PFOS induces bone loss is not well understood. Our research is aimed at examining the effects of PFOS on osteoblastic activity and investigating the toxicological mechanisms of PFOS-induced bone loss. Cell proliferation, ALP activity, bone nodule formation, ROS levels, and cell apoptosis were assessed after treating osteoblasts with different concentrations of PFOS.

View Article and Find Full Text PDF

Background: Polytrauma and hemorrhagic shock can lead to direct and indirect liver damage involving intricate pathophysiologic mechanisms. While hepatic function has been frequently highlighted, there is minimal research on how the receptor activator of the NF-κB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system is regulated in the liver following trauma. Furthermore, cross-talking complement and toll-like-receptor (TLR) systems can contribute to the posttraumatic response.

View Article and Find Full Text PDF

Introduction: This study aimed to investigate the levels of interleukin-1 receptor antagonist (IL-1RA), receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), interleukin-1β, osteopontin, and tissue necrotizing factor-α in teeth with external invasive resorption (EIR) in comparison to the contralateral healthy tooth of the same patient.

Methods: Twenty-nine patients with at least one tooth with EIR and a healthy tooth on the contralateral side (33 paired teeth) were included. Data on patient demographics and medical and dental history were collected.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!